Natera reported outstanding Q1 2023 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. The company's product revenues witnessed a ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and ...

Large prospective study to evaluate a non-invasive prenatal screening test EDEN is designed as a definitive prospective study of Natera’s integrated prenatal risk assessment test, which combines ...

An expectant mom got a $750 bill for a blood test to check for genetic abnormalities in her baby. Then she tried to figure out why it was so high. Offered a cash price for a prenatal genetic test? It ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...